Drugs / Fecal Microbiota Transplant (FMT)
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05664113 | Jul 2025 → Dec 2026 expected | digestive system disorder | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT01704937 | Nov 2012 → May 2014 | Clostridium infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05253768 | Mar 2024 → Mar 2025 | type 2 diabetes mellitus | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03678493 | Sep 2019 → Feb 2022 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Masonic Cancer Center, University of Minnesota | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT04622475 | Nov 2020 → Aug 2021 | acute graft versus host disease | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fecal Microbiota Transplant (FMT) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622475 ↗ |
| Known as | stool transplant | “Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via colonoscopy” NCT01704937 ↗ |
| Action | Restore | “FMT improved postantibiotic recovery of microbiota diversity, restored several depleted obligate anaerobic commensals” PMID 37235836 ↗ May 2023 |
| Route | Other | “via colonoscopy or nasogastric tube” NCT01704937 ↗ |